Merck & Co., Inc. operates as a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. Keytruda is its leading oncology treatment.
Merck & Co., Inc. operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for MRK.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). MRK Stock Intelligence Report. [stoxpulse.com/stocks/mrk]
Disclaimer: The information on this page about Merck & Co., Inc. (MRK) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Merck & Co., Inc..
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 16%
Mar 31
AGEN Early Access Revenues Signal a New Path Ahead...
3h ago
Is Agenus Stock a Hold Amid Valuation and Funding ...
3h ago
StoxPulse AI results for MRK: Pulse Score 48.5/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$302.26B
P/E Ratio
16.5
EPS
$-1.72
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+7.7%
Sep 25
+13.1%
Dec 25
+3.0%
Mar 26
+16.0%
Beat estimates 4 of 4 quarters (100%)
Merck & Co., Inc. operates as a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. Keytruda is its leading oncology treatment.
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
Friday's session: top gainers and losers in the dow jones index
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention
Merck (MRK) Recently Broke Out Above the 20-Day Moving Average